AN2 Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
AN2 Therapeutics, Inc. (ANTX) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$452.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$719.00K, a 139.83% decline year-over-year.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $267.00K.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$159.00K.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$2.51M, a 880.43% decline year-over-year.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$1.51M.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$807.00K, a 178.65% decline from fiscal 2023.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $1.03M, a 38.86% decline from fiscal 2022.
- AN2 Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.68M, a 20.98% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$719.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$452.00K 10-Q · filed 2026-08-11 | -$611.00K derived: sum of 3 quarters · filed 2026-08-11 | -$3.12M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $267.00K 10-Q · filed 2026-05-11 | $108.00K derived: sum of 2 quarters · filed 2026-05-11 | -$2.40M derived: sum of 3 quarters · filed 2026-05-11 | -$600.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$2.67M derived: sum of 2 quarters · filed 2026-03-17 | -$867.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.51M 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$2.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$708.00K derived: sum of 2 quarters · filed 2026-08-11 | -$1.35M 10-Q · filed 2025-11-12 | -$2.17M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.16M 10-Q · filed 2026-08-11 | $345.00K derived: sum of 3 quarters · filed 2026-08-11 | $667.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$645.00K 10-Q · filed 2026-05-11 | -$1.46M derived: sum of 2 quarters · filed 2026-05-11 | -$1.14M derived: sum of 3 quarters · filed 2026-05-11 | -$343.00K derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | -$815.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$493.00K derived: sum of 2 quarters · filed 2026-03-17 | $302.00K derived: sum of 3 quarters · filed 2026-03-17 | -$807.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $322.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.12M derived: sum of 2 quarters · filed 2025-11-12 | $8.00K 10-Q · filed 2025-11-12 | $629.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$314.00K 10-Q · filed 2025-08-12 | $307.00K derived: sum of 3 quarters · filed 2025-08-12 | $286.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$1.11M 10-Q · filed 2025-05-13 | -$488.00K derived: sum of 2 quarters · filed 2025-05-13 | -$509.00K derived: sum of 3 quarters · filed 2025-05-13 | $659.00K derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $600.00K derived: sum of 2 quarters · filed 2025-03-25 | $1.77M derived: sum of 3 quarters · filed 2025-03-25 | $1.03M 10-K · filed 2025-03-25 | |
| 2023-09-30 | -$21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.15M derived: sum of 2 quarters · filed 2024-11-13 | $405.00K 10-Q · filed 2024-11-13 | $73.00K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $426.00K 10-Q · filed 2024-08-13 | $94.00K derived: sum of 3 quarters · filed 2024-08-13 | -$540.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$742.00K 10-Q · filed 2024-05-14 | -$1.07M derived: sum of 2 quarters · filed 2024-05-14 | -$1.71M derived: sum of 3 quarters · filed 2024-05-14 | $370.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$966.00K derived: sum of 2 quarters · filed 2024-03-29 | $1.11M derived: sum of 3 quarters · filed 2024-03-29 | $1.68M 10-K · filed 2024-03-29 | $958.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | -$634.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.44M derived: sum of 2 quarters · filed 2023-11-09 | $2.01M 10-Q · filed 2023-11-09 | $3.05M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $2.64M 10-Q · filed 2023-08-10 | $3.68M derived: sum of 3 quarters · filed 2023-08-10 | $3.08M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $566.00K 10-Q · filed 2023-05-11 | $1.61M derived: sum of 2 quarters · filed 2023-05-11 | $997.00K derived: sum of 3 quarters · filed 2023-05-11 | $2.06M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $431.00K derived: sum of 2 quarters · filed 2023-03-29 | $1.49M derived: sum of 3 quarters · filed 2023-03-29 | $1.39M 10-K · filed 2023-03-29 | |
| 2021-09-30 | -$609.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $449.00K derived: sum of 2 quarters · filed 2022-11-09 | $347.00K 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $956.00K 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | -$102.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |